PaxMedica Releases 2022 Shareholder Letter
PaxMedica, Inc. (PXMD)
Company Research
Source: GlobeNewswire
Company Anticipates Multiple Milestones in Next 12-24 Months TARRYTOWN, NY, Feb. 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms, today released a 2022 shareholder letter discussing its recent accomplishments and upcoming milestones. Dear Shareholders and Stakeholders, 2022 was an exciting year for PaxMedica. We reached several important milestones, and anticipate several others as we progress through 2023. PaxMedica’s most important objective is to initiate PAX-101 (suramin) clinical trials for the treatment of Autism Spectrum Disorder (ASD) in the U.S. To achieve that primary objective, we are following a well-thought-out strategic path, comprised of key goals that will help accelerate us towards our primary objective. The past year was highlighted by our
Show less
Read more
Impact Snapshot
Event Time:
PXMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PXMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PXMD alerts
High impacting PaxMedica, Inc. news events
Weekly update
A roundup of the hottest topics
PXMD
News
- PaxMedica's CEO and Malawi Health Official Discuss Urgent Medical Crisis in Bell2Bell Podcast [Yahoo! Finance]Yahoo! Finance
- PaxMedica's CEO and Malawi Health Official Discuss Urgent Medical Crisis in Bell2Bell PodcastGlobeNewswire
- PaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101 [Yahoo! Finance]Yahoo! Finance
- PaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101GlobeNewswire
- PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness [Yahoo! Finance]Yahoo! Finance
PXMD
Sec Filings
- 4/23/24 - Form 8-K
- 4/16/24 - Form 8-K
- 4/15/24 - Form ARS
- PXMD's page on the SEC website